KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Gross Profit: 2009-2024

Historic Gross Profit for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $2.3 billion.

  • Biomarin Pharmaceutical's Gross Profit rose 14.13% to $636.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year increase of 15.91%. This contributed to the annual value of $2.3 billion for FY2024, which is 20.48% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Gross Profit stood at $2.3 billion for FY2024, which was up 20.48% from $1.9 billion recorded in FY2023.
  • In the past 5 years, Biomarin Pharmaceutical's Gross Profit ranged from a high of $2.3 billion in FY2024 and a low of $1.3 billion during FY2020.
  • Moreover, its 3-year median value for Gross Profit was $1.9 billion (2023), whereas its average is $1.9 billion.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Gross Profit declined by 0.62% in 2020 and then increased by 20.48% in 2024.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Gross Profit stood at $1.3 billion in 2020, then grew by 2.96% to $1.4 billion in 2021, then climbed by 15.79% to $1.6 billion in 2022, then rose by 18.46% to $1.9 billion in 2023, then rose by 20.48% to $2.3 billion in 2024.